Angiotensin II type 1a receptor signals are involved in the progression of heart failure in MLP-deficient mice. 2007

Rie Yamamoto, and Hiroshi Akazawa, and Kaoru Ito, and Haruhiro Toko, and Masanori Sano, and Noritaka Yasuda, and Yingjie Qin, and Yoko Kudo, and Takeshi Sugaya, and Kenneth R Chien, and Issei Komuro
Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Japan.

BACKGROUND Angiotensin II (AT) is implicated in the development of cardiac remodeling, which leads to heart failure, and pharmacological inhibition of the AT type 1 (AT1) receptor has improved mortality and morbidity in patients of heart failure. The aim of this study was to elucidate the role of the AT1 receptor in disease progression in muscle LIM protein (MLP)-deficient mice, which are susceptible to heart failure because of defective function of mechanosensors in cardiomyocytes. RESULTS Hearts from MLP knockout (MLPKO) mice and MLP-AT1a receptor double knockout (DKO) mice were analyzed. MLPKO hearts showed marked chamber dilatation with cardiac fibrosis and reactivation of the fetal gene program. All of these changes were significantly milder in the DKO hearts. Impaired left ventricular (LV) contractility and filling were alleviated in DKO hearts. However, the impaired relaxation and downregulated expression of sarcoplasmic reticulum calcium-ATPase 2 were unchanged in DKO hearts. CONCLUSIONS The AT1a receptor is involved in progression of LV remodeling and deterioration of cardiac function in the hearts of MLPKO mice. These results suggest that blockade of the receptor is effective in preventing progression of heart failure in dilated cardiomyopathy.

UI MeSH Term Description Entries
D008297 Male Males
D009124 Muscle Proteins The protein constituents of muscle, the major ones being ACTINS and MYOSINS. More than a dozen accessory proteins exist including TROPONIN; TROPOMYOSIN; and DYSTROPHIN. Muscle Protein,Protein, Muscle,Proteins, Muscle
D002311 Cardiomyopathy, Dilated A form of CARDIAC MUSCLE disease that is characterized by ventricular dilation, VENTRICULAR DYSFUNCTION, and HEART FAILURE. Risk factors include SMOKING; ALCOHOL DRINKING; HYPERTENSION; INFECTION; PREGNANCY; and mutations in the LMNA gene encoding LAMIN TYPE A, a NUCLEAR LAMINA protein. Cardiomyopathy, Congestive,Congestive Cardiomyopathy,Dilated Cardiomyopathy,Cardiomyopathy, Dilated, 1a,Cardiomyopathy, Dilated, Autosomal Recessive,Cardiomyopathy, Dilated, CMD1A,Cardiomyopathy, Dilated, LMNA,Cardiomyopathy, Dilated, With Conduction Defect 1,Cardiomyopathy, Dilated, with Conduction Deffect1,Cardiomyopathy, Familial Idiopathic,Cardiomyopathy, Idiopathic Dilated,Cardiomyopathies, Congestive,Cardiomyopathies, Dilated,Cardiomyopathies, Familial Idiopathic,Cardiomyopathies, Idiopathic Dilated,Congestive Cardiomyopathies,Dilated Cardiomyopathies,Dilated Cardiomyopathies, Idiopathic,Dilated Cardiomyopathy, Idiopathic,Familial Idiopathic Cardiomyopathies,Familial Idiopathic Cardiomyopathy,Idiopathic Cardiomyopathies, Familial,Idiopathic Cardiomyopathy, Familial,Idiopathic Dilated Cardiomyopathies,Idiopathic Dilated Cardiomyopathy
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005260 Female Females
D005355 Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury. Cirrhosis,Fibroses
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D044140 Receptor, Angiotensin, Type 1 An angiotensin receptor subtype that is expressed at high levels in a variety of adult tissues including the CARDIOVASCULAR SYSTEM, the KIDNEY, the ENDOCRINE SYSTEM and the NERVOUS SYSTEM. Activation of the type 1 angiotensin receptor causes VASOCONSTRICTION and sodium retention. Angiotensin II Type 1 Receptor,Angiotensin Type 1 Receptor,Angiotensin Type 1a Receptor,Angiotensin Type 1b Receptor,Receptor, Angiotensin, Type 1a,Receptor, Angiotensin, Type 1b,Angiotensin AT1 Receptor,Angiotensin AT1a Receptor,Angiotensin AT1b Receptor,Angiotensin II Type 1a Receptor,Angiotensin II Type 1b Receptor,Receptor, Angiotensin II Type 1,Receptor, Angiotensin II Type 1a,Receptor, Angiotensin II Type 1b,AT1 Receptor, Angiotensin,AT1a Receptor, Angiotensin,AT1b Receptor, Angiotensin,Receptor, Angiotensin AT1,Receptor, Angiotensin AT1a,Receptor, Angiotensin AT1b

Related Publications

Rie Yamamoto, and Hiroshi Akazawa, and Kaoru Ito, and Haruhiro Toko, and Masanori Sano, and Noritaka Yasuda, and Yingjie Qin, and Yoko Kudo, and Takeshi Sugaya, and Kenneth R Chien, and Issei Komuro
August 1995, The Journal of biological chemistry,
Rie Yamamoto, and Hiroshi Akazawa, and Kaoru Ito, and Haruhiro Toko, and Masanori Sano, and Noritaka Yasuda, and Yingjie Qin, and Yoko Kudo, and Takeshi Sugaya, and Kenneth R Chien, and Issei Komuro
February 2001, Journal of the American Society of Nephrology : JASN,
Rie Yamamoto, and Hiroshi Akazawa, and Kaoru Ito, and Haruhiro Toko, and Masanori Sano, and Noritaka Yasuda, and Yingjie Qin, and Yoko Kudo, and Takeshi Sugaya, and Kenneth R Chien, and Issei Komuro
July 2006, Journal of the American Society of Nephrology : JASN,
Rie Yamamoto, and Hiroshi Akazawa, and Kaoru Ito, and Haruhiro Toko, and Masanori Sano, and Noritaka Yasuda, and Yingjie Qin, and Yoko Kudo, and Takeshi Sugaya, and Kenneth R Chien, and Issei Komuro
November 2009, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Rie Yamamoto, and Hiroshi Akazawa, and Kaoru Ito, and Haruhiro Toko, and Masanori Sano, and Noritaka Yasuda, and Yingjie Qin, and Yoko Kudo, and Takeshi Sugaya, and Kenneth R Chien, and Issei Komuro
February 2008, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
Rie Yamamoto, and Hiroshi Akazawa, and Kaoru Ito, and Haruhiro Toko, and Masanori Sano, and Noritaka Yasuda, and Yingjie Qin, and Yoko Kudo, and Takeshi Sugaya, and Kenneth R Chien, and Issei Komuro
July 2003, Journal of cardiovascular pharmacology,
Rie Yamamoto, and Hiroshi Akazawa, and Kaoru Ito, and Haruhiro Toko, and Masanori Sano, and Noritaka Yasuda, and Yingjie Qin, and Yoko Kudo, and Takeshi Sugaya, and Kenneth R Chien, and Issei Komuro
August 2005, Journal of hepatology,
Rie Yamamoto, and Hiroshi Akazawa, and Kaoru Ito, and Haruhiro Toko, and Masanori Sano, and Noritaka Yasuda, and Yingjie Qin, and Yoko Kudo, and Takeshi Sugaya, and Kenneth R Chien, and Issei Komuro
February 1998, Circulation,
Rie Yamamoto, and Hiroshi Akazawa, and Kaoru Ito, and Haruhiro Toko, and Masanori Sano, and Noritaka Yasuda, and Yingjie Qin, and Yoko Kudo, and Takeshi Sugaya, and Kenneth R Chien, and Issei Komuro
December 2017, American journal of physiology. Renal physiology,
Rie Yamamoto, and Hiroshi Akazawa, and Kaoru Ito, and Haruhiro Toko, and Masanori Sano, and Noritaka Yasuda, and Yingjie Qin, and Yoko Kudo, and Takeshi Sugaya, and Kenneth R Chien, and Issei Komuro
January 2012, Experimental animals,
Copied contents to your clipboard!